GSK Hails Success For Novel Antibiotic – But Reaching $1bn Sales Will Be A Challenge
Company Expects To File In H1 2023
Executive Summary
GSK is returning to its long heritage in antibiotics with a potential first-in-class drug that has just shown promise in urinary tract infection; hopes are that it can reach annual sales of $1bn.
You may also be interested in...
Questions Overshadow Roche’s Bid To Make Tecentriq First Adjuvant Liver Cancer Treatment
Despite recording the first success for an adjuvant drug therapy in hepatocellular carcinoma, Roche is likely to need longer-term safety and efficacy data before attempting a filing.
GSK Boosts Its Infectious Disease Portfolio With Brexafemme License
The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.
GSK Phase II Win Offers Hope For TB Breakthrough
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.